upcyte head welcome

upcyte technologies – expanded primary cells

…. have you ever been concerned that your cell based assay is not relevant enough to provide you with satisfying results?
…. have you ever been forced to reduce the number of data points simply by the limitation of appropriate assay cells?

The possibility to scale up mammalian cells economically and the loss of cell-type specific properties have long been two sides of a coin. A downside which had to be accepted when assay reproducibility and throughput were obligatory needs. upcyte technologies has managed to split this coin and is providing a solution which combines large scale cell expansion with physiological relevance.

By using the proprietary upcyte® protocol non-dividing primary cells are pushed back into proliferation without altering their most relevant tissue-specific characteristics. upcyte technologies can generate homogenous cell batches of up to 10 billion physiologically relevant cells from cell types which are otherwise limited. upcyte technologies provides assay-ready cells from various upcyted® human healthy or diseased tissues along with optimized medium formulations to make cell-based screening even more relevant and your early ADME-Tox screen more predictive.

 

ESTIV

Berlin (Germany) on Oct 15-17, 2018

AASLD - The liver meeting

San Francisco (USA) on Nov 10-13, 2018

 

And find more meetings here!

More publications citing upcyte hepatocytes, go to our updated list

 

We received a ZIM-BMWi grant for "upcyting" enterocytes (intestine) together with the University in Greifswald. We are very excited! Read more here.

upcyte technologies GmbH

Osterfeldstrasse 12-14
22529 Hamburg
Germany

Astrid: +49 (0) 176/22949908
Nikolett: +49 (0) 152/04072876
Lab: +49 (0) 40/63 730 308

info@upcyte.com

© 2018 by upcyte technologies GmbH // Osterfeldstrasse 12-14 // 22529 Hamburg // Germany